Both genetic and epigenetic alterations can control the progression of cancer. Epigenetics comprises several alterations to the DNA molecule that may alter the binding of proteins and thereby the expression of genes, and our knowledge about cancer-promoting epigenetic alterations is mostly limited to DNA methylation at promoters of tumor-suppressor genes. Today it is known that most cancer types harbor much more widespread and frequent epigenetic alterations, and the functional effect of these alterations still remains unclear.
The overarching aim of the project group is to increase our understanding of the causal effects of epigenetic alterations in breast cancer, and to utilize this knowledge to develop classification of breast cancer patients with clinical utility.
Project Group members
- Lai X, Geier OM, Fleischer T, ..., A. Frigessi, Towards personalized computer simulation of breast cancer treatment: a multi-scale pharmacokinetic and pharmacodynamic model informed by multi-type patient data. Cancer Res 2019, PubMed 31118201
- Fleischer T*, Tekpli X*, ..., Kristensen VN, DNA methylation at enhancers identifies distinct breast cancer lineages, Nat Commun 2017, PubMed 29123100
- Fleischer T*, Klajic J*, ..., Kristensen VN, DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival, Oncotarget 2017, PubMed 27911866
- Fleischer T, ..., Kristensen VN (2014), Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis, Genome Biol 2014, PubMed 25146004